Why Is uniQure N.V. $QURE Stock Down -38.07% Today? (Find out why any stock moved today on Tickeron.) • $QURE shares fell roughly 38% in Tuesday's session after the company released new four-year data on its Huntington's disease gene therapy. • The 48-month readout for AMT-130 (ifezuntirgene inilparvovec) missed statistical significance on a key efficacy measure, triggering the sell-off. • The composite Unified Huntington's Disease Rating Scale (cUHDRS) showed a 44% slowing of disease progression that was not statistically significant (p=0.144), versus an 80% slowing at 36 months. • Management attributed the weaker result to "survivor bias" in the external control group, not to a loss of treatment effect. • Analysts largely remained upbeat, noting the company's regulatory filing is anchored to highly significant 36-month data. • Traders are now watching for any FDA response to the company's already-submitted Biologics License Application (BLA). $ABVX $NKTR $RGNX $OCUL $CORT $SLNO